UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in ...

UK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed up with the London-based startup to develop its small, activating ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development ...

The RNA polymerase is responsible for the replication of viral genetic material and the activation of viral genes, and is ...

An activator protein bound to DNA at an upstream enhancer sequence can attract proteins to the promoter region that activate RNA polymerase (green) and thus transcription. The DNA can loop around ...

A groundbreaking study led by Li Yi, professor at the School of Life Sciences, was published in Nature on March 12, titled “Perception of viral infections and initiation of antiviral defence in rice”, ...

Pyogenes, the Edit-R platform comprises the three components required for gene editing in mammalian cells: (1) A plasmid encoding Cas9 nuclease, (2) a chemically-synthesized trans-activating RNA ...

RAR is a synthetic-modified RNA motif derived from the hepatitis C virus genome that is specifically recognized by RIG-I and induces innate immune activation, including production of interferon ...

Because some RNA granules are capable of motor-dependent movement along microtubules 59, sequestered mRNAs might be delivered to specific sites in the cell for later activation. These dynamic ...